Here's some of what is coming soon to NeurologyLive® this week.
News|Articles|October 27, 2025
2025 CNS Annual Meeting: Top Expert Interviews and Key Takeaways
Author(s)Isabella Ciccone, MPH
Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.
Advertisement
Advertisement
The NeurologyLive® team has been as busy as ever bringing you the latest clinical news and research updates in neurology over the past several months, including conducting several interviews with experts across a range of topics.
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
The phase 2 FENerations1 study is evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS with pediatric pharmacokinetic and safety findings not yet reported.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Advertisement
Advertisement